Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma (ALBO – Research Report) yesterday and set a price target of $84.00. The company's shares closed last Monday at $23.95, close to its 52-week low of $20.30. According to TipRanks.com, Moussatos has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.4% and a 36.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals. Albireo Pharma has an analyst consensus of Strong Buy, with a price target consensus of $76.00, which is a 243.6% upside from current levels.
https://www.tipranks.com/news/blurbs/wedbush-thinks-albireo-pharmas-stock-is-going-to-recover-4?utm_source=advfn.com&utm_medium=referral
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2022 bis Mai 2022 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mai 2021 bis Mai 2022 Click Here for more Albireo Pharma Charts.